By Brazil Stock Guide – Prescription drugs have become the main driver of healthcare costs in Brazil’s private system. According to the national regulator ANS, spending on pharmaceuticals has increased 86% since 2019 and now represents about 10% of total medical and hospital expenses. In oncology treatments, the surge is even more dramatic, with drug-related costs up 128% over the same period.
The data come from ANS’s Supplementary Health Care Map 2024, which shows that the number of procedures performed by private health plans has remained broadly stable, while total expenses continue to rise. The figures indicate that treatments are becoming more expensive, rather than more frequent — a pattern increasingly tied to the introduction of advanced therapies and precision medicine.
Nearly eight out of ten new procedures added to the mandatory coverage list in 2024 involved pharmaceuticals, most of them oral cancer drugs. This shift toward high-cost, technology-driven care is reshaping the cost structure of Brazil’s private healthcare system, as medication expenses grow faster than hospital or outpatient costs. Health insurers now face a mounting burden driven by innovation — and its price.
The regulator says the findings reflect the sector’s transformation under demographic pressure and rapid scientific progress. For operators, the challenge will be to balance access, sustainability and innovation in a system where the future of healthcare increasingly depends on the cost of medicine.
Leave a Reply